title: Immunological parameters and respiratory functions in patients suffering from atopic bronchial asthma after intravenous treatment with salmon calcitonin.
abstract: This study reports the effect of salmon calcitonin on airway function and peripheral blood parameters in asthmatic subjects. The premise for the study is that calcitonin is given to asthmatics that require systemic corticosteroids as a way to counter problems with calcium balance and osteoporosis, and that it has an immunosuppressive effect. Salmon calcitonin (100 IU) was administered to 18 patients with atopic bronchial asthma, and the following spirometric parameters were evaluated: forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), peak respiratory flow rate (PEFR) and forced expiratory flow rates at 25%, 50% and 75% of the forced vital capacity (FEF25%, FEF50% and FEF75%). Calcitonin significantly decreased the levels of FVC and FEV1 by 20 min after starting the infusion. The effect of 500 mg aminophylline, used as a reference drug in this study, was much more profound, with a significant increase in all investigated parameters. Also, the effect of salmon calcitonin on some immune parameters (white blood cell count, number of eosinophils, serum levels of immunoglobulins IgG, IgM and IgA, and serum levels of lymphocytes subpopulations CD3, CD4, CD8 and CD19) was determined in another group of 30 patients suffering from atopic bronchial asthma. Calcitonin at a dose of 100 IU/day subcutaneously for 3 days did not alter the immune parameters studied, thus rendering it safe for such and similar treatment schedules in a variety of medical conditions.
authors.affiliation: Department of Microbiology and Immunology, Silesian School of Medicine, Zabrze-Rokitnica, Poland.
authors.forename: H
authors.initials: H
authors.lastname: Kawalski
authors.forename: U
authors.initials: U
authors.lastname: Polanowicz
authors.forename: G
authors.initials: G
authors.lastname: Jonderko
authors.forename: E J
authors.initials: EJ
authors.lastname: Kucharz
authors.forename: W
authors.initials: W
authors.lastname: Krol
authors.forename: K
authors.initials: K
authors.lastname: Klimmek
authors.forename: A R
authors.initials: AR
authors.lastname: Gina
authors.forename: R
authors.initials: R
authors.lastname: Pieczyrak
authors.forename: J
authors.initials: J
authors.lastname: Slifirski
authors.forename: J
authors.initials: J
authors.lastname: Shani
mesh_terms: D000328:Adult; D000628:Aminophylline / Q000009:adverse effects / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D002000:Bronchospirometry; D002116:Calcitonin / Q000009:adverse effects / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007275:Injections, Intravenous; D008297:Male
chemical_list: D001993:Bronchodilator Agents; D007166:Immunosuppressive Agents; D000628:Aminophylline; C028815:salmon calcitonin; D002116:Calcitonin